Can we establish a hierarchy among trastuzumab biosimilar candidates?

The European patent for intravenous trastuzumab lapsed in 2017, and this stimulated research into a number of trastuzumab biosimilars. Quality assessment of their development and clinical results might enable establishment of a clinical hierarchy of these agents. This editorial will underline the ke...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivot, Xavier, Petit, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068097/
https://www.ncbi.nlm.nih.gov/pubmed/30002436
http://dx.doi.org/10.1038/s41416-018-0171-1
_version_ 1783343207975747584
author Pivot, Xavier
Petit, Thierry
author_facet Pivot, Xavier
Petit, Thierry
author_sort Pivot, Xavier
collection PubMed
description The European patent for intravenous trastuzumab lapsed in 2017, and this stimulated research into a number of trastuzumab biosimilars. Quality assessment of their development and clinical results might enable establishment of a clinical hierarchy of these agents. This editorial will underline the key points for consideration when determining such an evaluation.
format Online
Article
Text
id pubmed-6068097
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60680972019-08-01 Can we establish a hierarchy among trastuzumab biosimilar candidates? Pivot, Xavier Petit, Thierry Br J Cancer Editorial The European patent for intravenous trastuzumab lapsed in 2017, and this stimulated research into a number of trastuzumab biosimilars. Quality assessment of their development and clinical results might enable establishment of a clinical hierarchy of these agents. This editorial will underline the key points for consideration when determining such an evaluation. Nature Publishing Group UK 2018-07-13 2018-08-01 /pmc/articles/PMC6068097/ /pubmed/30002436 http://dx.doi.org/10.1038/s41416-018-0171-1 Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Editorial
Pivot, Xavier
Petit, Thierry
Can we establish a hierarchy among trastuzumab biosimilar candidates?
title Can we establish a hierarchy among trastuzumab biosimilar candidates?
title_full Can we establish a hierarchy among trastuzumab biosimilar candidates?
title_fullStr Can we establish a hierarchy among trastuzumab biosimilar candidates?
title_full_unstemmed Can we establish a hierarchy among trastuzumab biosimilar candidates?
title_short Can we establish a hierarchy among trastuzumab biosimilar candidates?
title_sort can we establish a hierarchy among trastuzumab biosimilar candidates?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068097/
https://www.ncbi.nlm.nih.gov/pubmed/30002436
http://dx.doi.org/10.1038/s41416-018-0171-1
work_keys_str_mv AT pivotxavier canweestablishahierarchyamongtrastuzumabbiosimilarcandidates
AT petitthierry canweestablishahierarchyamongtrastuzumabbiosimilarcandidates

Ejemplares similares